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In this paper, the protective eﬀect of the bioﬂavonoid quercetin on behaviors, antioxidases, and neurotransmitters in 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine-(MPTP-) induced Parkinson’s disease (PD) was investigated. Quercetin treatment (50mg/kg,
100mg/kg and 200mg/kg body weight) was orally administered for 14 consecutive days. The results show that quercetin treatment
markedlyimprovesthemotorbalanceandcoordinationofMPTP-treatedmice.Signiﬁcantincreaseswereobservedintheactivities
of glutathione peroxidase (GPx), superoxide dismutase (SOD), and Na+,K +-ATPase, AchE, the content of dopamine (DA) in the
quercetin plus MPTP groups compared to those in the MPTP group. Signiﬁcant reduction the 4-hydroxy-2-nonenal (4-HNE)
immunoreactivity in striatum of brains was observed in the quercetin plus MPTP groups in comparison to the MPTP group.
Taken together, we propose that quercetin has shown antiparkinsonian properties in our studies. More work is needed to explore
detailed mechanisms of action.
1.Introduction
Parkinson’s disease (PD), which is a type of regressive disease
of the central nervous system, is the second most common
disorder of the aging brain after Alzheimer’s disease. The
clinical manifestations are static tremors, myotonia, bradyki-
nesia, and poor balance. The main drug families that are
useful for treating motor symptoms are levodopa, dopamine
agonists, and MAO-B inhibitors [1].
PD models are divided into two broad categories: genetic
and toxic [2, 3]. Most of the data that addresses the eﬀects
of oxidative stress have been generated using toxic models
such as those produced by 1-methyl-4-phenyl-1, 2, 3, 6-
hydroxydopamine (MPTP), which damages the nigrostriatal
dopaminergic system.
The antioxidative activity of quercetin, which is a
bioﬂavonoid, has been studied [4]. Recent studies have
shown that quercetin crosses the blood-brain barrier (BBB)
[5] and protects HT-22 cells by prohibiting the formation
of reactive oxygen species (ROS), which is generated by glu-
tamic acid-induced oxidation toxicity and lipid peroxidation
[6].
In the present study, we investigated the neuropro-
tective eﬀects of quercetin to modify glutathione peroxi-
dase (GPx), superoxide dismutase (SOD), Na+,K +-ATPase,
immunoreactivity of 4-hydroxy-2-nonenal (4-HNE), acetyl-
cholinesterase (AChE) activities, and the level of dopamine
(DA) in the brain tissue in the MPTP-induced mouse model
of Parkinson’s disease.
2.MaterialsandMethods
2.1. Animals. Speciﬁc pathogen-free adult male C57BL/6
mice (25 ± 2g, body weight; 2–2.5 months old) were
housed in standard cages with wood shavings. Ten animals
per cage were kept in a room with a carefully controlled
ambient temperature (25◦C) and artiﬁcially illumination2 Evidence-Based Complementary and Alternative Medicine
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Figure 1:Theeﬀectofquercetinonthefalllatencyofrotarodtestin
a mice model of Parkinson’s disease (PD) induced by MPTP. Data
were expressed as mean ± SE for 10 mice in each group. ###: P<
0.001 as compared to the control group; ∗: P<0.05 as compared to
MPTP group; ∗∗: P<0.01 as compared to MPTP group.
(12hoursoflightfrom8:00AMto8:00PM).Allexperiments
were performed under the Guidelines of the Experimental
Laboratory Animal Committee of the Jilin Province.
2.2. Drugs. Quercetin (98%) and MPTP were purchased
from Sigma-Aldrich (St. Louis, MO, USA). All of the
other chemicals were of analytical grade and obtained from
standard commercial suppliers. MPTP was dissolved in
0.9% physiological saline, and quercetin was resuspended in
distilled water.
2.3.AnimalGroupingandTreatment. Themic ewer edi vided
into 5 groups (10 mice in each group): the control group,
the MPTP group (MPTP-treatment group), the low-dose
group (quercetin 50mg/kg body weight plus MPTP), the
middle-dose group (quercetin 100mg/kg body weight plus
MPTP), and the high-dose group (quercetin 200mg/kg
body weight plus MPTP). All quercetin plus MPTP groups
were orally administered the indicated concentration of
quercetin every 24h for 14 consecutive days. To evaluate
the eﬀects of quercetin in the PD mouse model, MPTP was
intraperitoneally injected with ﬁve consecutive injections at
a dose of 30mg/kg every 24h from day 10 to day 14 starting
at 1h after the oral administration of quercetin. An equal
volume of saline instead of MPTP was injected into the mice
in the control group.
2.4. Motor Behavior Analysis with the Rotarod Test. An accel-
erating rotarod test was used to measure motor balance and
coordination in mice as described previously by L’Episcopo
et al. [7]. The rotarod cylinder was accelerated from 4
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Figure 2: The eﬀects of quercetin on the activity of glutathione
peroxidase in a mice model of Parkinson’s disease (PD) induced
by MPTP. Data were expressed as mean ± SE for 10 mice in each
group.###: P<0.001 as compared to the control group; ∗: P<0.05
as compared to MPTP group; ∗∗∗: P<0.001 as compared to MPTP
group.
to 40rpm within 5 minutes, and the cutoﬀ time was 300
seconds. The total time that each mouse remained on the
rod was automatically recorded by a trip switch under the
ﬂoorofeachrotatingdrumthatwasactivatedbytheanimal’s
fall. The average time (fall latency) for three trials was
determined.
2.5. Tissue Sample. T h em i c ew e r es a c r i ﬁ c e da f t e rb e i n g
anesthetizedwithpentobarbitalsodium.Thebraintissuewas
isolate removed and divided equably into two parts.
One part of the brain tissues was immediately homoge-
nizedincold10mMTris-HCl,pH7.5(1/10w/v),with10up-
and-down strokes at approximately 12,000rpm in a Teﬂon-
glass homogenizer. The homogenates were centrifuged at
3000×g for 10min to yield a clear supernatant fraction as
the sample that was used for measuring the activity of GPx,
SOD, Na+,K +-ATPase, and AChE.
The other part of the brains was transferred into a
1.5mL plastic vial, then weighed and homogenized in iced-
cold HClO4(0.4M) using an ultrasonicator. After storage for
1h in ice, the homogenates were centrifuged at 12,000×g
for 15min at 4◦C. The supernatant was incubated with
am i x e db u ﬀer (20mM sodium citrate, 300mM K2HPO4,
2mM sodium ethylenediaminetetraacetic acid (Na2EDTA))
at the ratio (v/v) of 1:2 for 1h on ice and centrifuged at
12,000×gf o r1 5m i na t4 ◦C. The supernatant was collected
and ﬁltered through a 0.22mm ﬁlter and was subsequently
analyzed the level of the DA [8].
2.6. Biochemical Analysis. The GPx activity was determined
in accordance with a previously described method [9]w i t hEvidence-Based Complementary and Alternative Medicine 3
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Figure 3: The eﬀects of quercetin on the activity of superoxide
dismutase in a mice model of Parkinson’s disease (PD) induced
by MPTP. Data were expressed as mean ± SE for 10 mice in each
group. ###: P<0.001 as compared to the control group; ∗: P<0.05
as compared to MPTP group; ∗∗: P<0.01 as compared to MPTP
group.
minor modiﬁcations. The enzymatic activity of GPx was
represented as unit/mg protein, where 1 unit of GPx activity
was deﬁned as 1µM GSH that was depleted per minute.
The SOD activity was measured using the method of
Ohkawa et al. [10] to evaluate the ability of the xanthine-
xanthine oxidase system to inhibit the oxidation of oxymine.
Na+,K +-ATPase activity was determined using method
that has been described by Wyse et al. [11]. The reaction
mixture for the Na+,K +-ATPase activity assay contained the
following: 3mM MgCl2, 125mM NaCl, 20mM KCl, and
50mM Tris-HCl (pH 7.4) in a ﬁnal volume of 500µL. The
reaction was initiated by the addition of ATP to a ﬁnal
concentrationof3.0mM.Thecontrolsampleswereobtained
under the same conditions with the addition of 0.1mM
ouabain.Thesampleswereincubatedat37◦Cfor30min,and
the incubation was stopped by adding trichloroacetic acid
solution (10% TCA) with 10mM HgCl2.N a +,K +-ATPase
activity was calculated based on the diﬀerence between the
two assays (with ouabain/without ouabain). The speciﬁc
activity of the enzyme was expressed as mol Pi that was
released per hour per mg of protein (mol Pi/hour/mg
protein).
The activity of acetylcholinesterase (AchE) was estimated
using the method of Ellman et al. [12]. The samples were
homogenized in buﬀer medium I (0.32M sucrose, 5mM
Tris-HCl and 0.1mM EDTA) (1:10; w/v) and centrifuged
at 2400×g for 10min to obtain the low-speed supernatant.
T h eh o m o g e n a t e( 1 0 0 µL) was incubated in 1mL of a
solution containing 10mM 5,5-ditiobis (2-dinitrobenzoic)
acid (DTNB) (dissolved in potassium phosphate buﬀer pH
7.0) and 100mM potassium phosphate buﬀer (pH 7.5) as
well as 700µLw a t e rf o r2m i na t2 5 ◦C. Afterwards, 200µL
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Figure 4: Theeﬀect so fq u e r c eti no nt h eacti vi tyo fN a +,K +-ATPase
inamicemodelofParkinson’sdisease(PD)inducedbyMPTP.Data
were expressed as mean ± SE for 10 mice in each group. ##: P<0.01
ascomparedtothecontrolgroup; ∗:P<0.05ascomparedtoMPTP
group; ∗∗: P<0.01 as compared to MPTP group.
of acetylthiocholine (8mM, substrate) was added to the tube
test. The activity of AchE was spectroﬂuorometrically mea-
s u r e da t4 1 2n ma n de x p r e s s e da sh y d r o l y z e dA c h / m i n / m g
protein.
The protein concentration was measured using the
Bradford method [13] with bovine serum albumin as the
standard.
The level of DA was determined using HPLC, which was
equipped with an electrochemical (EC) detector that was
used for quantiﬁcation [8]. The level of DA was determined
using standard curves as references. The data were expressed
as ng/g tissue weight.
2.7. Immunohistochemistry. Immunohistochemical method
was taken in another batch of mice which were treated as the
“animal grouping and treatment.” The brains were quickly
removed and postﬁxed for 2 days with paraformaldehyde.
Immunohistochemical studies were performed on paraﬃn-
embedded midbrain sections. The 30µm thick transverse
sections were deparaﬃnized with xylene and reﬁxed with
Bouin’s solution for 20min. For inhibition of endogenous
peroxidase, the sections were incubated with 0.3% H2O2
in methanol for 30min. After rinsing in 10mM phos-
phatebuﬀered saline (PBS), the sections were incubated
with normal goat serum (Dako, diluted to 1:10) to inhibit
nonspeciﬁc binding of the antibodies. After incubation with
the polyclonal anti-4-hydroxy-2-nonenal (HNE) antibody
(1:400, Alpha Diagnostic International, San Antonio, TX,
USA) at 4◦C overnight, the sections were treated with
biotinylated secondary antibody for 1h at 37◦C, then with
streptavidin-peroxidase for 1h. Subsequently the sections
wereincubatedwith3,4-diaminobenzidine.Theresultswere
analyzed by counting the numbers of positive cells at 400x4 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Immunostaining of striatum with 4-HNE in a mice model of Parkinson’s disease (PD) induced by MPTP. Staining was present
within cell bodies. ###: P<0.001 as compared to the control group: ∗∗: P<0.01 as compared to MPTP group. (a) In control group, there
was a few of 4-HNE immunoreactivity. (b) MPTP group: compared with control group, MPTP markedly increased the immunoreactivity
of 4-HNE in mice striatum. (c) Low-dose group: no diﬀerence from MPTP group. (d) Middle-dose group: 4-HNE immunoreactivity
are signiﬁcantly reduced in striatum of brains in comparison to the MPTP group. (e) High-dose group: 4-HNE immunoreactivity are
signiﬁcantly reduced in striatum of brains in comparison to the MPTP group.
magniﬁcations on a microscope (Eclipse 80i, Nikon Corp.,
Japan). The average number of positive cells was used to
represent cell density.
2.8. Statistics. All of the data were expressed as the mean ±
SE. The statistical signiﬁcance of diﬀerences that were
detected in each parameter among the groups was evaluated
using one-way analysis of variance (ANOVA) followed by
Fisher’s protected least signiﬁcant diﬀerence (PLSD) com-
parison tests for post hoc t-tests.
3. Results
3.1.TheResultsoftheRotarodTest. Intherotarodtest,thefall
latencyoftheMPTPgroupwassigniﬁcantlyshorterthanthat
of the control group (P<0.001). Compared with the MPTP
group, the quercetin low-dose group showed no signiﬁcant
change whereas the middle- and high-dose groups exhibited
signiﬁcantly longer fall latencies (P<0.05 and P<0.01,
resp.). The results are shown in Figure 1.
3.2.TheEﬀectonAntioxidases. MPTP-treatedmicedisplayed
perturbations in the activities of GPx, SOD, and Na+,
K+-ATPase. Pretreatment with quercetin augmented the
activities of GPx, SOD, and Na+,K +-ATPase in the mouse
brain tissue. The results are shown in Figures 2, 3 and 4.
3.3. The Result of Immunohistochemistry. Immunoreactivity
of 4-HNE was markedly increased in the striatum of the
mice PD brain compared to the control group brain that
displayed weak immunoreactivity of 4-HNE. We assessed
the relationship of the antioxidant eﬀect of quercetin in
PD mice through phenotypic observation along with 4-
HNE using microscopy. Quercetin (100, 200mg/kg) reduced
the immunoreactivity of 4-HNE in the striatal neurons of
C57/BL mice. All results shown in Figure 5.
3.4. The Eﬀect on AchE. We analyzed the eﬀects of quercetin
on the activity of AchE in the brain tissues. AchE was lower
in the MPTP group than in the control group. AchE in
administration of quercetin groups showed higher than that
MPTP group. The results were showed in Figure 6.
3.5. The Eﬀe c to ft h eL e v e lo fD A .The eﬀects of quercetin
on the levels of DA in the brain are shown in Figure 7.T h e
brain levels of DA decreased in the MPTP group comparedEvidence-Based Complementary and Alternative Medicine 5
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Figure 6: The eﬀects of quercetin on the activity of acetyl-
cholinesterase in a mice model of Parkinson’s disease (PD) induced
by MPTP. Data were expressed as mean ± SE for 10 mice in each
group. ###: P<0.001 as compared to the control group; ∗: P<0.05
as compared to MPTP group; ∗∗: P<0.01 as compared to MPTP
group.
to the control group (P<0.01). Compared with the MPTP
group, the quercetin pretreatment groups attenuated the
MPTP-induced DA depletion.
4. Discussion
MPTP is metabolized into the toxic cation 1-methyl-4-
phenylpyridinium (MPP+) by the enzyme MAO-B in glial
cells. MPP+ primarily kills dopamine-producing neurons
in the part of the brain that is called the pars compacta
of the substantia nigra and interferes with a component of
mitochondrial metabolism, which induces cell death and
causes the buildup of free radicals and toxic molecules [14].
The rotarod test is designed to evaluate the motor
coordination and balance of the mouse by forcing the animal
to run. In the present study, the results of the rotarod
test reveal that the quercetin concentrations at the middle
(100mg/kg) or high (200mg/kg) doses enhance the motor
activity of MPTP-treatment mice. This ﬁnding shows that
quercetin plays an important role in the developmental
processes of the internal system regulating the mouse motor
behavior and suggests that quercetin improves the balance of
MPTP-treatment mice.
Recent research has suggested that the brain may
eﬃciently metabolize superoxide but may have diﬃculties
regarding hydrogen peroxide elimination [15]. In this study,
the MPTP group showed lower GPx and SOD activities.
These results indicate that MPTP reduces the elimination of
hydrogen peroxide and free radicals in the brain. Quercetin
pretreatment in the MPTP-induced group showed increased
GPx and SOD activities. These results suggest that the
elimination of superoxide anion was enhanced by quercetin.
Hydrogen peroxide, which is generated during superoxide
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Figure 7:Theeﬀectsofquercetinonthelevelofdopamineinamice
model of Parkinson’s disease (PD) induced by MPTP. Data were
expressed as mean ± SE for 10 mice in each group. ###: P<0.001 as
compared to the control group; ∗: P<0.05 as compared to MPTP
group; ∗∗: P<0.01 as compared to MPTP group.
dismutation, was suﬃciently removed by GPx after the
pretreatment with quercetin. 4-HNE is a major membrane
lipid peroxidation product [16]. Additionally, we analyzed
the eﬀect of quercetin on the level of 4-HNE in striatal
neurons. As expected, quercetin (100, 200mg/kg body
weight) reduced the 4-HNE immunoreactivity in neurons
of PD model mice. It shows that quercetin could decrease
the product of lipid peroxidation. These results indicate the
mechanism of quercetin neuroprotection eﬀects.
The Na+,K +-ATPase establishes the ionic concentration
balance that maintains the cell’s potential. Recent research
has suggested that the Na+,K +-ATPase is susceptible to free
radical-induced damage [17]. In addition, Na+,K +-ATPase
activity is reduced in disorders of the nervous system. Na+,
K+-ATPase activity was examined. The results show that
Na+,K +-ATPaseactivityissigniﬁcantlyreducedintheMPTP
group compared to that in the control group. Quercetin
reversed the MPTP-induced reduction in Na+,K +-ATPase
activity. This result indicates that quercetin protects against
MPTP-induced oxidative stress and maintains the resting
membrane potential of neurons.
Dopamine and acetylcholine, which play important
roles in bodily movement, should maintain the dynamic
equilibrium in the extrapyramidal system. Suﬀerers of PD
experience dystonia when the cholinergic nerve is placed in
an advantage status. AchE is an enzyme that degrades (via its
hydrolytic activity) the neurotransmitter Ach. Acetylcholine
behaves as an excitatory neurotransmitter at neuromuscular
junctions[18].Inthecurrentstudy,weexaminedtheactivity
of AchE in the brain tissue of mice. We found that the
AchE activity in the MPTP group signiﬁcantly decreased
comparedwiththecontrolgroupandthatquercetinreversed
the MPTP-induced reduction in AchE activity. This result6 Evidence-Based Complementary and Alternative Medicine
suggests that quercetin reduces the level of acetylcholine by
enhancing the AchE activity, which may mediate quercetin-
induced improvements in motor balance and coordination
of MPTP-treated mice.
Dopamine is the primary neurotransmitter that is
involved in motor functions. The loss of dopamine directly
aﬀects physical movements and is considered a cardinal
feature of PD in humans or in animal models of the
disease [19]. MPTP causes a signiﬁcant reduction in brain
dopamine levels. The results of our present study show
that the administration of quercetin markedly improves
MPTP-induced dopamine depletion in the brain tissue
whichissigniﬁcantlyalteredfollowingMPTPtreatment.The
enhancement of dopamine content by quercetin may restore
the changes in locomotor activity.
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